HealthQuill Drugs
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular disease in diabetic adults with chronic kidney disease.
Drugs Health Medical

Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod

Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.

Read More
A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s and 1990s when millions died of the virus, including many in the United States, according to the World Health Organization.
Drugs Health Pharma

US aid pause to take ‘world back to 1980s, 1990s’ on fighting HIV: WHO 

A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s.

Read More
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug regulator in the adult population. 
Drugs Health Pharma

AstraZeneca-Daiichi’s breast cancer drug gets broader US nod

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.

Read More
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.
Drugs Health Medical Pharma

Biogen-Eisai’s Alzheimer’s drug gets 4-weekly dosing nod in US

Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.

Read More
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Pharma

AstraZeneca to invest $570 million in Canada to boost innovation, clinical delivery

HQ Team January 26, 2025: Pharmaceutical giant AstraZeneca has announced plans to invest US$570 million in Canada over the next decade, positioning the.

Read More
China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic blood disorder.
Drugs Health Medical

China’s YolTech starts gene editing trial for treating a blood disorder 

China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic.

Read More
The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may cause hospitalisation and death due to a “rare but serious” allergic reaction.
Drugs Health Medical Pharma

US drug regulator issues warning on certain multiple sclerosis drugs

The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may.

Read More
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed at a third-party manufacturing facility.
Drugs Health Medical Pharma

FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold

The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.

Read More
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development, automation and software.
Drugs Health Pharma

Daiichi Sankyo sets up robotic lab in US to speed up drug discovery

Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.

Read More
GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high
Drugs Pharma Research

New insights on GLP-1 drugs: Benefits and risks unveiled

HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.

Read More